Please visit answersincme.com/860/27391-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the available evidence informs sequencing strategies with antibody-drug conjugates for the optimization of care in HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.